Johnson & Johnson’s coronavirus vaccine has shown 66% effectiveness in preventing moderate and severe Covid-19, according to interim data released from a phase 3 trial of the first single-dose vaccine.
The effectiveness rate reported on Friday by the world’s largest healthcare company is lower than that of jabs already authorized by BioNTech / Pfizer, Moderna and Oxford / AstraZeneca. The rate is also not directly comparable because the trial excluded mild cases of the disease.
The vaccine has shown some protection against the 501. V2 variant, which first appeared in South Africa, although its efficacy was 57% in trials there. The jab has shown an efficiency rate of 72 percent in the United States and 66 percent in Latin America.
Alex Gorsky, CEO of J&J, called the results a “critical milestone”. The company intends to file an emergency use authorization application in the United States in early February and, if granted, will be able to ship vaccines immediately.
“Our goal has always been to create a simple and effective solution for as many people as possible, and to have maximum impact to help end the pandemic,” he said.
The vaccine was 85% effective in preventing severe Covid-19. Twenty-eight days after the jab, it offered “complete protection” against hospitalization and death. Protection was uniform across all age groups, including those over 60, the company said.
The trial included nearly 44,000 participants and accumulated 468 symptomatic cases of Covid-19, in both groups that received the placebo and those that received the vaccine. No significant security issues have been reported.
NOT A WORD pledged to price the inoculation on a “not-for-profit basis” for the duration of the pandemic – around $ 10 per injection. The US, UK and EU have agreements for the J&J vaccine of at least 100m, 30m, and 200m doses, respectively.
As countries face supply shortages, the J&J jab could help expand supply in a form just a hit. It does not require ultra-cold temperatures for transportation and storage, and can be stored at 2 ° C to 8 ° C for three months.
Paul Stoffels, scientific director, said it would potentially protect hundreds of millions of people from serious and fatal consequences.
“A single dose vaccine is considered by the World Health Organization to be the best option in pandemic situations, improving access, distribution and compliance.”
The results come after Novavax and Moderna announced plans for vaccine trials designed to fight the 501. V2 variant, after their jabs seemed less effective against it. J&J has not said he will seek to reformulate his vaccine, despite data also suggesting that it is less effective.
Novavax reported an 89% efficacy rate in a UK Phase 3 trial and said Thursday evening he was likely to apply for UK clearance in early February.
Europe is currently loggerheads with AstraZeneca, oversupply of its vaccine after manufacturing issues prompted the drugmaker to say it would provide fewer doses in the first quarter of the year.